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ABSTRACT 
Vascular endothelial growth factor (VEGF) is implicated in peritoneal membrane 
remodeling that limits ultrafiltration in peritoneal dialysis (PD). While the exact mechanism 
of VEGF induction in PD is unclear, VEGF concentrations in drained dialysate correlate with 
IL-6 levels suggesting a link between these cytokines. Human peritoneal mesothelial cells 
(HPMC), the main source of IL-6 and VEGF in the peritoneum, do not bear cognate IL-6 
receptor and are thus unable to respond to classical IL-6 receptor signaling. Here, we show 
VEGF release by HPMC is controlled by IL-6 in combination with its soluble receptor (IL-6 
trans-signaling). Although IL-6 and soluble IL-6 receptor (sIL-6R) alone had no effect on VEGF 
production, stimulation of HPMC with IL-6 in combination with sIL-6R promoted VEGF 
expression through a transcriptional mechanism involving STAT3 and SP4. Induction of VEGF 
was functionally active and conditioned medium from HPMC cultured with IL-6 and sIL-6R 
promoted angiogenic endothelial tube formation, which could be blocked by silencing SP4. 
To verify these in vitro observations, induction of peritoneal inflammation in wild type and 
IL-6-deficient mice further demonstrated IL-6 involvement in the control of SP4, VEGF and 
new vessel formation, confirming the role for IL-6 trans-signaling in these processes. Taken 
together these findings identify a novel mechanism linking IL-6 trans-signalling and 
angiogenesis in the peritoneal membrane. 
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INTRODUCTION 
The efficacy of peritoneal dialysis (PD) as a treatment modality largely depends on the 
peritoneal membrane integrity. Dysfunction of the peritoneum as a dialysis organ may result 
from progressive membrane injury occurring over time on PD. The underlying 
pathophysiological mechanisms involve a gradual rise in small solute transport due to an 
increase in peritoneal perfusion and a decrease in peritoneal hydraulic conductance due to 
tissue fibrosis.1 Both these processes are related to peritoneal angiogenesis. On the one 
hand, an increase in peritoneal vascularity increases the surface area available for solute 
diffusion and leads to rapid dissipation of the osmotic gradient that drives ultrafiltration. On 
the other hand, angiogenesis is a prominent feature of tissue repair, scar formation and 
fibrosis. Indeed, it has been estimated that up to 75% of patients with ultrafiltration failure 
may have increased vascular surface area.2;3 Moreover, peritoneal biopsies taken from PD 
patients show that fibrosis occurs significantly more often in the presence of vasculopathy,4 
and the density of peritoneal blood vessels and sub-mesothelial and perivascular fibrosis are 
significantly greater in patients with membrane failure.4-6 Animal models of PD confirm the 
existence of an inverse correlation between increased vascularization and ultrafiltration.7 
These studies suggest that a decline in ultrafiltration could be partially abrogated by anti-
angiogenic therapy.7 
Vascular endothelial growth factor (VEGF) is the most important pro-angiogenic 
mediator.8 The impact of VEGF on peritoneal vascularity is demonstrated by the association 
of genetic polymorphisms determining increased VEGF production with increased peritoneal 
solute transport.9 Moreover, the rates of VEGF appearance in the dialysate are elevated in 
patients with high peritoneal transport status.10;11 
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Several mechanisms are implicated in peritoneal VEGF induction in PD.12 One of the 
factors involved has been suspected to be interleukin-6 (IL-6), since IL-6 concentrations in 
the drained dialysate correlate with peritoneal solute transport rates13-15 and dialysate levels 
of VEGF. 10;14 Interestingly, it has been demonstrated that the peritoneal mesothelium is the 
main source of both VEGF16;17 and IL-6.18;19 Although VEGF can be induced by several 
inflammatory cytokines20, IL-6 has not been classically viewed as a driver of VEGF production 
in mesothelial cells, as these do not express the cognate IL-6 receptor (IL-6R).21 On the other 
hand, however, they do express gp130, a signal transduction element for IL-6, which allows 
them to respond to IL-6 in the presence of soluble IL-6R (sIL-6R). Indeed, this process of so-
called IL-6 trans-signaling plays critical role in controlling chemokine production and 
contributes to successful resolution of inflammation.21 The mechanism appears to be 
particularly active in the acute phase of peritonitis when mesothelial cells release large 
quantities of IL-619 and infiltrating leukocytes shed sufficient levels of sIL-6R.21 Interestingly, 
viral IL-6 (vIL-6) that binds directly to gp130 in a process resembling IL-6 trans-signaling, is 
also capable of inducing VEGF in mesothelial cells.22  
We have therefore hypothesized that IL-6 together with sIL-6R might be important in 
controlling VEGF production in human peritoneal mesothelial cells (HPMC). Here, we 
characterized the transcriptional regulation of VEGF in HPMC and identified transcription 
factors STAT3 and SP4 as forming a novel axis linking IL-6 and VEGF production in the 
peritoneum.  
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RESULTS 
 
Induction of VEGF by IL-6 and sIL-6R in mesothelial cells 
Since mesothelial cells are the main source of peritoneal VEGF, we have examined 
whether VEGF production by human peritoneal mesothelial cells (HPMC) can be regulated 
by IL-6 – either directly through classical IL-6 receptor signaling or IL-6 trans-signaling. 
Indeed, neither IL-6 nor sIL-6R alone had significant effect on VEGF protein release. 
However, simultaneous exposure to IL-6+sIL-6R resulted in a significant time- and dose-
dependent increase in VEGF secretion (Fig. 1A and 1B). The greatest effect was achieved 
with both IL-6 and sIL-6R at a dose of 100 ng/ml. This effect was confirmed by specific 
blocking experiments. Here, antibodies against either IL-6 or sIL-6R, but not with control IgG, 
inhibited the induction of VEGF by HPMC (Fig. 1C). The effect exerted by a combination of IL-
6 and sIL-6R on VEGF secretion was accompanied by a corresponding increase in VEGF mRNA 
(Fig. 1D). These observations prompted us to examine in more detail the signaling events 
leading to VEGF gene induction. 
 
Activation of VEGF gene promoter by IL-6 and sIL-6R  
To investigate how the IL-6+sIL-6R complex impacts on the activity of the VEGF gene 
promoter, HPMC were transiently transfected with VEGF luciferase reporter gene constructs 
and stimulated with IL-6 and sIL-6R. This resulted in a time-dependent increase in VEGF 
promoter activity, which peaked at 6 hours (Fig. 2A). Exposure for 6 hours to IL-6 or sIL-6R 
alone had no stimulatory effect on the full length VEGF promoter. In contrast, the 
combination of IL-6 and sIL-6R strongly increased the activity of the VEGF promoter (Fig. 2B). 
To identify VEGF promoter regions mediating the response to IL-6 trans-signaling, functional 
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ϱ’-deletions of the VEGF promoter were generated. Truncation of the promoter region 
spanning positions -268 to -53 resulted in a loss of VEGF promoter activity to respond to 
stimulation with IL-6+sIL-6R (Figure 2C). This result suggested that the region identified 
comprised essential regulatory elements for the VEGF promoter activity. The in silico analysis 
predicted that the region contained high affinity binding sites for the transcription factors 
SP1 and SP4. To determine which of these transcription factors was regulated by IL-6+sIL-6R, 
electrophoretic mobility shift assays (EMSA) was performed. 
 
Activation of the transcription factor SP4 by IL-6 and sIL6-R 
EMSA was performed using biotin-labeled double-stranded oligonucleotides 
corresponding to positions -59 to -82 (SP4) and -80 to -103 (SP1) of the VEGF promoter. 
Analysis of nuclear extracts from cells stimulated with IL-6+sIL-6R showed formation of a 
prominent DNA-protein complex with a consensus oligonucleotide for SP4 binding (Fig. 3A). 
No binding was however seen with a consensus motif for SP1. Nuclear extracts from cells 
stimulated singly with IL-6 and sIL-6R failed to produce any effect.  
To verify the specificity of SP4 binding, EMSA was performed with a 100-fold molar 
excess of an unlabeled SP4 consensus oligonucleotide (Fig. 3B). This competition assay 
inhibited detection of the SP4-DNA complex. In turn, EMSA with a specific anti-SP4 antibody 
led to a supershift of the DNA-protein complex (Fig. 3B). Furthermore, transfection of a 
mutant construct specific to the SP4 binding site completely eliminated VEGF promoter 
activation after IL-6+sIL-6R stimulation (Fig. 3C). 
 
Effect of STAT3 blockade on VEGF production 
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As SP4 has not been typically associated with IL-6 signal transduction, we examined the 
activation of STAT3, a key regulator of IL-6 signaling.23 Indeed, stimulation of HPMC with IL-
6+sIL-6R resulted in a time-dependent induction of STAT3, but also of SP4 mRNA (Fig. 4A and 
4B). To determine if there exists a link between STAT3, SP4 and VEGF, the expression of 
STAT3 gene was blocked by RNA interference. These experiments showed that STAT3-
targeting siRNA, but not a scrambled siRNA control, inhibited STAT3 itself at a protein and 
mRNA level (Fig. 4C and 4D). It also inhibited SP4 and VEGF induction by IL-6+sIL-6R (Fig. 4E 
and 4F).  
 
Effect of SP4 blockade on VEGF production and angiogenesis 
To further confirm the involvement of SP4 in VEGF production and biological activity, 
HPMC were stimulated with IL-6+sIL-6R in the presence of either SP4-targeting siRNA or 
scrambled siRNA. The SP4 blockade resulted in a significant inhibition of VEGF protein 
release (Fig. 5A). To test the functional properties of the VEGF production, conditioned 
medium from stimulated HPMC was transferred to endothelial cell cultures and the 
formation of capillaries assessed. Incubation of human umbilical vein endothelial cells (of the 
EA.hy926 line) in the presence of conditioned medium from IL-6+sIL-6R-stimulated HPMC 
significantly increased endothelial cell tube formation. Similar degree of stimulation was 
observed when conditioned medium from HPMC treated with scrambled siRNA was used. 
However, endothelial cell angiogenesis was significantly less in response to conditioned 
medium from HPMC treated with siRNA against SP4 (Fig. 5B). This effect was not unique to 
specific features of EA.hy926 endothelial cells, but was also observed in cultures of human 
dermal microvascular endothelial cells (Supplemental Fig. 1).  
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Effect of IL-6 signaling on peritoneal Sp4 and Vegf expression in mice 
To test whether IL-6 signaling modulates Vegf expression during peritoneal 
inflammation, wild-type (WT) and IL-6-deficient (IL6-/-) mice were challenged (i.p.) with a 
cell-free supernatant prepared from of a clinical isolate of Staphylococcus epidermidis 
(SES).21 At designated time points, Sp4 and Vegf expression in the samples of parietal 
peritoneum was analyzed by qPCR. As illustrated in Fig. 6A, SES-induced inflammation in WT 
mice was associated with a time-dependent increase in Vegf mRNA expression. In contrast, 
Vegf expression was significantly less in IL6-/- mice. To assess whether this effect was related 
to sIL-6R activity, WT mice were treated with SES together with soluble gp130 (sgp130), 
which inhibits IL-6 trans-signaling by the IL-6+sIL-6R complex, but does not inhibit classic IL-6 
signaling through IL-6R.24 Addition of sgp130 significantly decreased Vegf expression in WT 
mice, which resembled the effect seen in IL6-/- mice and indicated that sIL-6R-mediated 
effects were involved in regulation of VEGF expression in the inflamed peritoneum.  
Having identified SP4 as a mediator of IL-6 trans-signaling in human cells, we next 
examined peritoneal expression of Sp4 in mice. Induction of peritoneal inflammation with 
SES led to a time-dependent increase in Sp4 expression in WT mice, but not in IL6-/- animals. 
In WT mice administered with sgp130, the expression of Sp4 followed the pattern seen in 
IL6-/- mice (Fig. 6B). 
 
Effect of IL-6 signaling in mice on peritoneal expression of genes essential for VEGF activity 
To determine whether VEGF induced in the peritoneum by IL-6-signaling can initiate 
events leading to increased vascular permeability and angiogenesis, we examined expression 
of several key endothelial-specific targets involved in these processes.25 These included VEGF 
receptors (Vegfr2 and Vegfr3), junctional proteins – vascular endothelial cadherin (VE-Cad) 
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and platelet/endothelial cell adhesion molecule 1 (Pecam1), markers of arterial commitment  
– neuropilin 1 (Nrp1) and ephrinB2 (Efnb2), and a marker of lymphatic commitment – 
podoplanin (Pdpn). Expression of all these angiogenesis-related targets increased 
significantly within 24 hours of SES-induced inflammation in WT mice but not in IL6-/- mice 
and not in WT mice receiving sgp130 (Fig. 7). 
 
Effect of IL-6 signaling on peritoneal vasculature during recurrent inflammation in mice 
To test whether these acute consequences of increased IL-6 signaling are associated 
with changes in peritoneal vasculature in the long term, we analyzed the parietal 
peritoneum of WT and IL6-/- mice challenged repeatedly with SES, as described previously.26 
After four sequential rounds of acute inflammation, the parietal peritoneum of WT animals 
appeared only modestly vascularized, but consistently showed increased numbers of vessels 
staining positively for PECAM-1 (CD31) and podoplanin (gp38) in comparison with IL6-/- mice 
(Supplemental Fig.2). 
 
Effect of STAT3/SP4-mediated IL-6 signaling on dialysate-induced VEGF expression in 
peritonitis 
As peritoneal effluents may contain high levels of IL-6 and sIL-6R during peritonitis, we 
have asked whether such effluents could induce VEGF in HPMC through a signaling pathway 
identified. Confirming earlier reports,21;27 we have detected significantly elevated 
concentrations of IL-6 and sIL-6R in the dialysate drained from PD patients during an acute 
phase of peritonitis (Fig. 8A). When an exemplary PD effluent from a patient with peritonitis 
was added to the culture medium, it stimulated VEGF, STAT3 and SP4 mRNA expression in a 
concentration-dependent manner (Fig. 8B). The increase in VEGF mRNA was reduced to 
Deleted: see 
Deleted: can be
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control levels in the presence of either STAT3 siRNA or SP4 siRNA, but not of the scrambled 
siRNA (Fig. 8C). Interestingly, the inhibition of STAT3 signaling resulted also in a decreased 
expression of SP4 and STAT3 itself. In contrast, the SP4blockade reduced the expression of 
SP4, but not of STAT3.  
 
 
DISCUSSION 
The diversity of IL-6 functions is now well appreciated.28 These pleiotropic activities 
are partly related to the complexity of IL-6 signaling, which allows even cells without the 
cognate IL-6R to respond to IL-6. Here, we demonstrate through a series of in vitro and in 
vivo experiments and the analysis of clinical samples from PD patients that a mechanism of 
IL-6 trans-signaling can contribute significantly to peritoneal VEGF production. In this 
respect, we have found that the complex of IL-6 and sIL-6R but not IL-6 alone is capable of 
inducing de novo VEGF synthesis in HPMC. In the clinical setting, this is most likely to occur 
during peritonitis since sIL-6R can be then delivered by shedding from infiltrating 
neutrophils.21;29 Indeed, we have observed that peritoneal inflammation induced in mice by 
S. epidermidis,21 a major causative microorganism of PD-associated peritonitis, resulted in an 
up-regulation of peritoneal Vegf expression. In contrast, the animals deficient in IL-6 failed to 
produce such a response. A similar lack of effect could be observed in wild-type mice treated 
with sgp130. These findings indicated that the induction of Vegf was controlled through sIL-
6R rather than by the membrane-bound IL-6R. This mechanism has previously been 
demonstrated to be instrumental in coordinating leukocyte trafficking during peritonitis.21 
Since STAT3 is the major signal transducer downstream of gp13023;30 and its 
involvement in VEGF gene regulation has already been postulated,31-33 we have examined 
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the consequences of STAT3 inhibition in HPMC. Indeed, the blockade of STAT3 resulted in an 
inability of the IL-6+sIL-6R complex to induce VEGF. Surprisingly, however, the progressive 
ϱ’-deletion analysis mapped the IL-6+sIL-6R response element of the VEGF promoter in 
HPMC to a region that did not contain STAT3 binding elements. Instead, it did contain high 
affinity binding sites for SP4. Subsequent experiments using EMSA and site-directed 
mutagenesis confirmed that it was SP4 driving VEGF gene expression in response to IL-6 
trans-signaling. Moreover, the blockade of STAT3 inhibited SP4 expression, which positioned 
STAT3 upstream of SP4 in the signaling cascade. Whilst the targeting of other transcription 
factors by STAT3 is recognized,34 the induction of SP4 has not been reported before. The 
existence of such a signaling axis in vivo was further supported by the observation that S. 
epidermidis-induced peritoneal inflammation either in IL-6-/- mice or in WT mice 
administered with sgp130 did not produce an increase in peritoneal Sp4 expression.  
The potential of IL-6 to drive VEGF expression has been observed in several cancer 
cells31;32;35-37 and implicated in tumor-associated angiogenesis.38;39 Interestingly, it has been 
demonstrated that anti-IL-6 antibody siltuximab reduced STAT3 activation and angiogenesis 
in IL-6-producing intraperitoneal ovarian cancer xenografts and reduced VEGF levels in 
patients with ovarian cancer.40 The exact role of SP4 in these processes remains to be 
established. The experiments using RNA interference suggested that SP4 might contribute to 
the regulation of basal VEGF expression in some pancreatic cancer cells lines.41 The 
involvement of SP4 could also be inferred from the observation that the down-regulation of 
VEGF expression by cyclooxygenase inhibitors in human colon cancer cells was associated 
with proteasomal degradation of SP4.42 
Ablation of STAT3 has long been considered an attractive therapeutic strategy for IL-
6-mediated inflammation and cancer.43;44 Our findings suggest that SP4 activity is 
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downstream of STAT3 activation in response to IL-6 trans-signaling. Thus, a therapeutic 
targeting of SP4 may block specific aspects of IL-6 signaling, whilst leaving STAT3 activity 
intact. That blocking SP4 can indeed produce viable biological effects could be demonstrated 
by experiments that showed a decrease in angiogenesis induced by conditioned media from 
HPMC exposed to the IL-6+sIL-6R complex in the presence of SP4-silencing RNA. 
The consequences of VEGF up-regulation by IL-6 trans-signaling in the setting of PD 
can be twofold. As VEGF is a potent vascular permeabilizing agent, its rise during acute 
peritonitis will cause extravasation of fluid rich in plasma proteins, which together with 
migrating leukocytes will form an inflammatory infiltrate essential for the clearance of 
infection. The process would be self-limiting given the massive, but short-lived increase in 
intraperitoneal IL-6 levels21;27 and the role of IL-6 trans-signaling in suppressing neutrophil-
specific chemokines21 and promoting neutrophil apoptosis.45 Indeed, it has been 
demonstrated that the IL-6+sIL-6R complex can induce STAT3- and VEGF-mediated vascular 
leakage through microvascular endothelial cells.46  
On the other hand, repeated episodes of peritonitis and the persistent IL-6+sIL-6R-
mediated VEGF stimulation may lead to formation of new hyperpermeable blood vessels, as 
found in many chronic inflammatory diseases.47 The accumulation of fibrin in tissues favors 
fibroblast migration and subsequent extracellular matrix synthesis. In this respect, it has 
recently been demonstrated that recurrent peritoneal inflammation in mice leads to tissue 
fibrosis through a process that is strictly dependent on IL-6, albeit in this particular model 
related to STAT1 and IFN- signaling.26 Moreover, it has been demonstrated that 
experimental peritoneal fibrosis in mice could be reduced by antagonizing VEGF through 
soluble VEGF type I receptor.48 We observed that SES-induced inflammation in WT mice was 
associated with increased expression of key mediators of VEGF signaling, new vessel 
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formation 25 and vascular remodeling.49 In this respect, increased expression of Pecam1 and 
VE-Cad likely reflect endothelial cell expansion in vivo but might also be a secondary 
response, either to transient rearrangement of intercellular junctions that underlie increased 
permeability or to degradation of junctional proteins by inflammation-induced proteases.50 
Importantly, these increases in endothelial markers were mediated directly by IL-6 trans-
signaling as they did not occur in IL-6-/- mice and could be reduced in WT mice by specific 
blockade with sgp130.  
Moreover, these early events in IL-6 signaling during acute inflammation may also 
contribute to chronic changes in the peritoneal vasculature. We have observed increased 
immunostaining for PECAM-1 and podoplanin in WT mice subjected to repeated episodes of 
peritonitis compared with IL-6-/- mice. Of particular interest is the increased number of 
podoplanin-positive cells in this setting, as increased expression of podoplanin was 
consistently detected in PD patients with encapsulating peritoneal sclerosis (EPS). 51;52 
Furthermore, recent data from the GLOBAL study showed that patients who developed EPS 
had earlier had higher dialysate levels of IL-6 during PD.53 
These two scenarios would fit well into the concept that depending on a 
pathophysiological context, IL-6 can either be crucial for host defense or promote chronic 
disease.28 Here, we demonstrate that dialysate IL-6 and sIL-6R can act together through the 
trans-signaling pathway controlled by the STAT3-SP4 axis to up-regulate mesothelial VEGF 
production during peritonitis. The identification of this novel mechanism that controls 
peritoneal VEGF expression at the transcriptional level may help to understand better how 
peritoneal inflammation and angiogenesis contribute to adverse peritoneal membrane 
remodeling during peritoneal dialysis.  
Deleted: an 
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CONCISE METHODS 
 
Materials 
Unless stated otherwise, all chemicals were from Sigma-Aldrich (St Louis, MO, USA) and 
all culture plastics were Falcon from Becton Dickinson (Franklin Lakes, NJ, USA). Cell culture 
media and buffers were from Biochrom AG (Berlin, Germany) and fetal calf serum was from 
Invitrogen (Darmstadt, Germany). Human recombinant IL-6 and sIL-6R were from R&D 
Systems (Wiesbaden, Germany). Antibodies against STAT3 and SP4 were from Santa Cruz 
Biotechnology, Inc. (Heidelberg, Germany).  
 
Mesothelial cell culture 
HPMC were isolated from the specimens of omentum obtained from consenting patients 
undergoing elective abdominal surgery. Cells were cultured and characterized as described 
in detail elsewhere.20 For the experiments, cells were rendered quiescent by serum 
deprivation for 48 hours and then stimulated with IL-6 and/or sIL-6R as specified in the 
legends to figures. All experiments were performed with cells no older than from the third 
passage to minimize the number of senescent cells, as this may affect the level of VEGF 
released.54 
 
Endothelial cell culture and tube formation assay 
Human umbilical vein endothelial cells (HUVEC) of the EA.hy926 line55 were kindly 
donated by Dr. CJ Edgell (University of North Carolina, Chapel Hill, USA). For the tube 
formation assay, Matrigel (Corning, Tewksbury, MA, USA) was poured onto a 96-well plate 
(50 µl/well) and solidified at 37°C for 30 min. Endothelial cells (2 × 104 cells/well) were 
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seeded onto the Matrigel and cultured in MCDB131 medium (Thermo Fisher Scientific, 
Waltham, MA USA) with or without 10% (v/v) conditioned medium from HPMC treated with 
as described in the legends to figures. Capillary networks of tubes formed were 
photographed under the microscope (Zeiss Axiovert 40 CFL Oberkochen, Germany) and five 
randomly selected fields from each well were analyzed for total capillary length using ImageJ 
1.43 software.56 
 
Immunoassays  
Concentrations of VEGF, IL-6 and sIL-6R were measured using DuoSet® Immunoassay Kits 
;R&D SǇsteŵsͿ. All assaǇs ǁere desigŶed aŶd perforŵed as per ŵaŶufacturer’s iŶstructioŶs. 
 
Gene expression analysis 
The expression of target genes was assessed with reverse transcription and quantitative 
PCR (RT-qPCR), essentially as described previously.20 PCR conditions and primer sequences 
were as specified in Supplemental Data.  
 
DNA Constructs and Reporter Plasmids 
Progressiǀe VEGF ϱ’-deletion luciferase plasmids (pLuc 2068, pLuc 1340, pLuc 840, pLuc 
318, and pLuc 102) were kindly provided by Dr. A. Scholz (Charité-Universitätsmedizin, 
Berlin, Germany). The constructs were generated as reported previously,57 and checked for 
the correct length by restriction digest. To target the SP4 binding site at position -73 to 75 
(TGA) within the VEGF promoter, the desired sequence (AAA) was inserted into the pLuc 
VEGF 318 construct using the Q5 site-directed mutagenesis kit (New England BioLabs, 
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Franfurt, Germany) with forward primer 5′- GGGGCGGGCCaaaGGCGGGGTCCC -3′ and 
reverse primer 5′- GGGGGGCGGGGACAGGCG -3′. 
 
Transfection studies 
Transient transfection and luciferase assays were performed as previously described in 
detail.20 Transfections with siRNAs were performed with the siRNA Transfection Reagent and 
siRNAs for STAT3 (sc-44275), SP4 (sc-36545), or with scrambled siRNA control (sc-37007) as 
per ŵaŶufacturer’s iŶstructioŶs ;all ŵaterials froŵ SaŶta Cruz BiotechŶologǇ, Heidelberg, 
Germany).  
 
Computational analysis of the VEGF promoter 
The human VEGF promoter region -268 to -51 (GenBank NT_007592.15) was analyzed by 
PROMO virtual laboratory (http://alggen.lsi.upc.es/cgi-
bin/promo_v3/promo/promoinit.cgi?dirDB=TF_8.3) for the presence and location of 
potential transcription factor binding sites. 
 
Nuclear extracts and electrophoretic mobility shift assay 
Nuclear extracts were prepared using the NE-PER Nuclear and Cytoplasmic Extraction Kit 
(Thermo Scientific, Darŵstadt, GerŵaŶǇͿ accordiŶg to the ŵaŶufacturer’s iŶstructioŶs. The 
extracts obtained were aliquoted and stored at -80°C. Oligonucleotide probes were labeled 
with the Biotin 3' End DNA Labeling Kit (Thermo Scientific). For the electrophoretic mobility 
shift assay (EMSA) the following probes were used (the corresponding region of the VEGF 
promoter is given in brackets): SP4 - ϱ’- GCGGGCCGGGGGCGGGGTCCCGGC -ϯ’ ;-131 to -154), 
Sp1 - ϱ’- TCGCCTGTCCCCGCCCCCCGGGGC -ϯ’ ;-109 to -132). Each binding mixture (20 µl) for 
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EMSA contained 5 µg nuclear extract, 20 fmol labeled double-stranded probe, 1 µg poly-
dI/dC, and 2 µl 10 x reaction buffer and was incubated at room temperature for 30 min. The 
protein-DNA complexes were then analyzed by electrophoresis in 6% non-denaturing 
polyacrylamide gels and visualized using a LightShift Chemiluminescent EMSA Kit (Thermo 
Scientific). 
 
Western blotting 
Cell extracts were prepared as described,58 electrophoresed on sodium dodecyl sulfate-
polyacrylamide gels and Western blotted using antibodies against STAT3 and SP4 (Santa Cruz 
Biotechnology), GAPDH (Hytest, Turku, Finland), and appropriate secondary peroxidase-
conjugated IgG (Dianova, Hamburg, Germany). The bands obtained were visualized and 
analyzed using Enhanced Chemiluminescence Detection System (Thermo Scientific) and 
Image J 1.43 software (National Institutes of Health, USA). 
 
Peritoneal dialysis effluent 
Peritoneal effluent was obtained from consenting patients undergoing continuous 
ambulatory PD. Dialysate was collected either from stable PD patients after a routine 4-hr 
dwell or from the first bag drained from patients presenting with an episode of peritonitis. 
Samples were processed as described previously.59 
 
Animal experiments  
All animal procedures were performed under appropriate licenses and according to 
institutional animal care guidelines. The experiments were performed in weight-matched 7- 
to 12-wk-old inbred C57BL/6J wild-type (WT) and IL-6-deficient (IL6-/-) mice, as previously 
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described.45 Peritoneal inflammation was established through i.p. administration of 500 µl of 
a cell-free supernatant (SES) prepared from S. epidermidis isolated from a PD patient, as 
detailed elsewhere.60 Repeated challenge with SES was used to model recurrent peritoneal 
inflammation, essentially as described previously.26 Animals were sacrificed at designated 
time points and specimens of peritoneal peritoneum were collected and snap frozen in liquid 
nitrogen. The tissue samples were then homogenized in Tri Reagent (Invitrogen) and total RNA 
was prepared according to the manufacturer’s iŶstructioŶs. Additional biopsy samples were 
processed for immunohistochemistry, as described26 and subsequently stained with 
antibodies against anti-CD31 (eBioscience) and podaplanin (BioLegend). Antibody labeling was 
detected using biotinylated secondary antibodies (Dako), the Vectastain ABC kit and 
diaminobenzidine chromagen (Vector Laboratories). Sections were counterstained with 
hematoxylin. Quantification of antibody staining was performed using the Leica QWin 
microscope imaging software (Jones, GW. et al., 2015 J. Exp. Med. 212:1793). 
 
Statistics 
Statistical analysis was performed using GraphPad Prism 6.05 software (GraphPad 
Software). The data were analyzed with the t-test or repeated measures analysis of variance 
for paired data (in vitro experiments) or unpaired data (animal experiments), as appropriate. 
Results were expressed as means ± SEM. Differences with a P value <0.05 were considered 
significant. 
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Figure legends 
 
Figure 1. Induction of VEGF in HPMC by a combination of IL-6 and sIL-6R. (A): Kinetics of 
VEGF secretion by HPMC treated with IL-6 (10 ng/ml) and sIL-6R (25 ng/ml) either singly or in 
combination; *P<0.05 vs. control cells at each time point, n=6; (B): Dose effect of IL-6 and 
sIL-6R on VEGF release over the period of 48 hours; *P<0.05 vs. untreated cells; (C): Blockade 
of the effect of the IL-6+sIL-6R complex. HPMC were treated with IL-6+sIL-6R (both at 100 
ng/ml) for 48 hours in the presence of 10 µg/ml of antibodies against either IL-6 (MAB206, 
R&D Systems) or sIL-6R (MAB227, R&D Systems). An additional group received an irrelevant 
antibody of the same class and at the same dose; *P<0.05 vs. cells not exposed to 
antibodies, #P<0.05 vs. cells treated with an irrelevant antibody; n=5; (D): Induction of VEGF 
mRNA by IL-6 and/or sIL-6R. HPMC were treated with IL-6 and sIL-6R (both at 100 ng/ml) 
either singly or in combination for 48 hours, *P<0.05 vs. untreated cells n=4).  
 
Figure 2. Identification of sequences in the human VEGF promoter responsive to 
stimulation with the IL-6+sIL-6R complex. Cell were transiently transfected with VEGF 
promoter constructs and stimulated with IL-6 and/or sIL-6R (both at 100 ng/ml), as 
indicated. Luciferase activity was determined as described in Methods. (A): Time effect of 
the IL-6+sIL-6R complex on the full-length VEGF promoter activity *P<0.05 vs. unstimulated 
control, n=3; (B): Full-length VEGF promoter activity after 6 hours of stimulation with IL-6 
and/or sIL-6R, n=4; (C): Effect of progressiǀe ϱ’-deletions of the VEGF promoter on its activity 
upon stimulation with IL-6+sIL-6R for 6 hours; *P<0.05 vs. unstimulated controls, n=4. 
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Figure 3. Identification of SP4 as a transcription factor mediating human VEGF promoter 
induction by the IL-6+sIL-6R complex. (A-B): Cells were stimulated with IL-6+sIL-6R at 100 
ng/ml for 6 hours, the nuclear fractions were obtained and analyzed with EMSA. In A, EMSA 
was performed with consensus oligonucleotide probes for SP1 and SP4; In B, formation of 
nuclear complexes with SP4 probe was assessed either in the presence of 100-fold molar 
excess of unlabeled VEGF DNA (resulting in a reduced shift – a lower arrow) or in the 
presence of SP4-specific antibody (resulting in supershift – an upper arrow). (C): Effect of 
site-directed mutagenesis in the SP4 binding site within the VEGF promoter on its activity 
after stimulation with IL-6+sIL-6R. #P<0.05 vs. relevant control, n=4. 
 
Figure 4. The role of STAT3 in SP4-mediated VEGF induction by the IL-6+sIL-6R complex.  
(A-B): Kinetics of STAT3 and SP4 mRNA induction in HPMC treated with IL-6+sIL-6R (both at 
100 ng/ml); *P<0.05 vs. control cells at each time point, n=4; (C-F): Effect of STAT3 silencing 
on STAT3, SP4 and VEGF expression. Cells were transiently transfected with either STAT3 
siRNA or scrambled (Scramb) siRNA and then stimulated with IL-6+sIL-6R (both at 100 ng/ml) 
for 9 hours. Cells were assessed for STAT3 protein expression by Western blotting (C) and 
mRNA expression by qPCR for STAT3 (D), SP4 (E), and VEGF (F). In C, a representative 
immunoblot is presented together with quantified data from 4 independent experiments. In 
C-F *P<0.05 vs. cells stimulated with IL-6+sIL-6R in the absence of siRNA, n=4. 
 
Figure 5. Effect of SP4 on VEGF-mediated endothelial cell tube formation. 
(A): Cells were transiently transfected with either SP4 siRNA or scrambled (Scramb) siRNA, 
stimulated with IL-6+sIL-6R (both at 100 ng/ml) for 24 hours and then assessed for VEGF 
secretion, n=5. (B): Effect of conditioned medium (10% v/v) from HPMC treated as in (A) on 
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endothelial cell tube formation within 16 hours. *P<0.05 vs. cells stimulated with IL-6+sIL-6R 
in the absence of siRNA, n=4. Representative phase contrast images (magnification 100 X) 
are presented in order corresponding to experimental groups as shown in graph from left to 
right. 
 
Figure 6. Effect of IL-6 signaling on peritoneal Sp4 and Vegf expression in mice. WT and 
IL6-/- mice were intra-peritoneally administered with SES and then analyzed at defined time 
points for Sp4 (A) and Vegf (B) expression in the parietal peritoneum. An additional group of 
WT animals received SES together with sgp130 (150 ng/mouse); *P<0.05 vs. WT mice at the 
same time point, n=4 mice per condition.  
 
Figure 7. Effect of IL-6 signaling on peritoneal expression of endothelial-specific targets 
Mice were treated as in Fig. 6 and analyzed for peritoneal expression of Vegfr2 (A), Vegfr3 
(B), Pecam1 (C), VE-Cad (D), Nrp1 (E), Efnb2 (F), and Pdpn (G). *P<0.05 vs. WT mice at the 
same time point, n=4 mice per condition.  
 
Figure 8. IL-6 signaling contributes to VEGF release by HPMC during peritonitis. (A): IL-6 
and sIL-6R levels in dialysates drained either from stable PD patients after a routine 4-hr 
dwell (n=20) or from patients with peritonitis at first presentation (n=11); the data are 
presented as box and whiskers plots, with the median, 25th and 75th percentiles, and range 
of data indicated; *P<0.05 between the groups; (B): The dose effect of exemplary PD 
effluent drained during peritonitis on VEGF (top), STAT3 (middle) and SP4 (bottom) mRNA 
expression in HPMC. Cells were treated with increasing doses of effluent for 24 hours. 
*P<0.05 vs. untreated controls, n=4; (C): Cells were transiently transfected with 10 µM 
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STAT3 siRNA, SP4 siRNA, or scrambled siRNA, as indicated. After that cells were exposed to 
peritoneal effluent (25% v/v) from a PD patient with peritonitis for 24 hours and assessed for 
mRNA expression of VEGF (top), STAT3 (middle), and SP4 (bottom). *P<0.05 vs. cells treated 
with the dialysate in the absence of siRNAs, n=4.  
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SUPPLEMENTAL DATA 
 
Gene expression analysis 
The expression of target genes was assessed with reverse transcription and quantitative 
PCR (RT-qPCR). Total RNA was extracted with the PerfectPure RNA Cultured Cell Kit (5 Prime, 
Hamburg, Germany), reverse transcribed into cDNA with random hexamer primers, and 
amplified with real-time qPCR on the Applied Biosystems 7500 Fast Real-Time PCR system 
(Applied Biosystems, Darmstadt, Germany). The reaction was carried out in ϭϰ μl reactioŶ 
ǀoluŵes coŶtaiŶiŶg Ϯ μl of cDNA ;ϮϬ ŶgͿ, specific seŶse aŶd aŶti-sense primers (250 nM 
eachͿ, aŶd 7 μl Poǁer SYBR GreeŶ PCR Master Miǆ ;Applied BiosǇsteŵsͿ. PCR priŵers ǁere 
synthesized by TIB Molbiol (Berlin, Germany) and their sequences were as follows:  
 VEGF (GenBank NM_001171623.1):  
forǁard ;ϱ’-AAGGAGGAGGGCAGAATCAT-ϯ’Ϳ,  
reǀerse ;ϱ’-ATCTGCATGGTGATGTTGGA-ϯ’Ϳ;  
 STAT3 (GenBank NM_139276.2):  
forǁard ϱ’- GGCCATCTTGAGCACTAAGC-ϯ’Ϳ,  
reǀerse ;ϱ’-CGGACTGGATCTGGGTCTTA -ϯ’Ϳ;  
 SP4 (GenBank NM_003112.3):  
forǁard ϱ’-TCAGCAGCAAGGACAAGATG -ϯ’Ϳ,  
reǀerse ;ϱ’- AAGCCTCTTGCCAGGTTGTA -ϯ’Ϳ;  
 β2M (GenBank NM_004048.2):  
forǁard ;ϱ’- GTGCTCGCGCTACTCTCTCT-ϯ’Ϳ,  
reǀerse ;ϱ’- CGGCAGGCATACTCATCTTT -ϯ’Ϳ.  
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Primers for murine targets were as follows:  
 Sp4 (GenBank NM_009239.4):  
forǁard ;ϱ’- GCCTGCTCCTGTCCTAACTG -ϯ’Ϳ,  
reǀerse ;ϱ’- CTCGGAGGTGAGAGGTCTTG -ϯ’Ϳ;  
 Vegf (GenBank NM_001025250.3):  
forǁard ;ϱ’- CAGGCTGCTGTAACGATGAA -ϯ’Ϳ,  
reǀerse ;ϱ’- GCATTCACATCTGCTGTGCT -ϯ’Ϳ.  
 β2m (GenBank NM_009735.3):  
forward (ϱ’- GAAATCCAAATGCTGAAGAACG-ϯ’Ϳ, 
reǀerse ;ϱ’- CAAATGAATGTTCAGAGCATCATG -ϯ’Ϳ 
 Pecam1 (GenBank NM_008816.2):  
forǁard ;ϱ’- AGAGACGGTCTTGTCGCAGT -ϯ’Ϳ,  
reǀerse ;ϱ’- TACTGGGCTTCGAGAGCATT -ϯ’Ϳ;  
 VE-Cad (GenBank NM_009868.4):  
forǁard ;ϱ’- ACCGAGAGAAACAGGCTGAA -ϯ’Ϳ,  
reǀerse ;ϱ’- AGACGGGGAAGTTGTCATTG -ϯ’Ϳ;  
 Vegfr2 (GenBank NM_010612.2):  
forǁard ;ϱ’- GGCGGTGGTGACAGTATCTT -ϯ’Ϳ,  
reǀerse ;ϱ’- GTCACTGACAGAGGCGATGA -ϯ’Ϳ;  
 Vegfr3 (GenBank NM_008029.3):  
forǁard ;ϱ’- GCTGTTGGTTGGAGAGAAGC -ϯ’Ϳ,  
reǀerse ;ϱ’- GAGCCACTCGACACTGATGA -ϯ’Ϳ;  
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 Efnb2 (GenBank NM_010111.5):  
forǁard ;ϱ’- CTCAACTGTGCCAGACCAGA -ϯ’Ϳ,  
reǀerse ;ϱ’- CTTGTTGGACCGTGATTCCT -ϯ’Ϳ;  
 Nrp1 (GenBank NM_008737.2):  
forǁard ;ϱ’- GGAGCTACTGGGCTGTGAAG -ϯ’Ϳ,  
reǀerse ;ϱ’- ACCGTATGTCGGGAACTCTG -ϯ’Ϳ;  
 Pdpn (GenBank XX):  
forǁard ;ϱ’- XX -ϯ’Ϳ,  
reǀerse ;ϱ’- XX -ϯ’Ϳ;  
  
 
After an initial activation step for 2 min at 50°C and denaturation at 95°C for 10 min, 40 
cycles of 15 sec at 95°C, and 1 min at 60°C were performed. Specificity of the reaction was 
verified by melting curve analysis at the end of each series of assays. The relative amount of 
gene transcript was calculated by the cycle threshold method using the Applied Biosystems 
7500 System v.1.2.3 software and normalized for the endogenous refereŶce ;βϮ-
microglobulin). 
 
VEGF promoter, EMSA oligonucleotide sequences and site-directed mutagenesis primer 
 
-267 
GGGCGCGTGTCTCTGGACAGAGTTTCCGGGGGCGGATGGGTAATTTTCAGGCTGTGAACCTTGGTG
GGGGTCGAGCTTCCCCTTCATTGCGGCGGGCTGCGGGCCAGGCTTCACTGAGCGTCCGCAGAGCCC
GGGCCCGAGCCGCGTGTGGAAGGGCTGAGGCTCGCCTGTCCCCGCCCCCCGGGGCGGGCCGGGGG
CGGGGTCCCGGCGGGGCGGAGCCATGCGCCCCCCCCTTTTTTTTTTAAAAGTCGGCTGGTAGCGGGG
AGGatcgcggaggcttggggcagccgggtagctcggaggtcgtggcgctgggg+50 
 
EMSA oligo sequences for SP1 and SP4 
GCGGGCCGGGGGCGGGGTCCCGGC SP4 -59 to -82 
TCGCCTGTCCCCGCCCCCCGGGGC SP1 -80 to -103 
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Site directed mutagenesis of SP4 sequences 
GGGGCGGGCCaaaGGCGGGGTCCC site directed mutagenesis forward Primer 
 
Nucleotides written in CAPITAL LETTERS correspond to VEGF promoter sequence -267 to 0. 
Nucleotides written in small letters correspond to VEGF gene sequence +1 to+50. 
 
A sequence in dark green was used as a synthethic oligo for SP1 EMSA experiments  
 
A sequence in light green was used as a synthethic oligo for SP4 EMSA experiments. Mutated 
SP4 sequence is written in small blue letters.  
 
Fig. S1 Effect of SP4 on VEGF-mediated tube formation by human dermal microvascular 
endothelial cells (HDMEC). Cells were transiently transfected with either SP4 siRNA or 
scrambled (Scramb) siRNA, and stimulated for 16 hrs with conditioned medium (10% v/v) 
from HPMC treated without or with IL-6+sIL-6R (both at 100 ng/ml) for 24 hours. *P<0.05 vs. 
cells stimulated with IL-6+sIL-6R in the absence of siRNA, n=4. Representative phase contrast 
images (magnification 100 x)  
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Fig. S2 Effect of IL-6 signaling in mice on peritoneal vasculature following repeated 
peritonitis. WT and IL-6-/- mice receiǀed ϰ coŶsecutiǀe doses of SES ;i.p.Ϳ adŵiŶistered at 7‐
day intervals. Histological eǀaluatioŶ ǁas recorded oŶ daǇ‐ϰ9 post first SES challeŶge. 
Sections were stained for either PECAM-1 (CD31) (A, B) or podoplanin (C, D). Representative 
40x magnification (insert panels: 400x magnification) fields are shown. Scores displayed in 
Panels B and D reflect digital assessments of immunohistochemistry staining as described in 
Materials and Methods. 
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